FOLR1 and ovarian cancer: The in vivo targeting of the folate receptor alpha (FRα) has also been reported in several other studies, of which Tummers et al. described the feasibility for detection of primary breast and ovarian cancer using EC17 (emission 520 nm), including the aim to detect LNMs in vivo.